Described are receptor ligands of transient receptor potential cation channel subfamily V member 4 (TRPV4), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating ocular disorders.

Described herein are methods and pharmaceutical formulations for treating dry eye disease.

Described herein are methods and pharmaceutical formulations for treating dry eye disease.

According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A.sub.1-A.sub.2b or, particularly, the A.sub.2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy.sup.1 or Het.sup.A; Cy.sup.1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy.sup.1 group is optionally substituted by one or more R.sup.4a substituents; Het.sup.A represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more hetermatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy.sup.2 or Het.sup.B; Cy.sup.2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy.sup.2 group is optionally substituted by one or more R.sup.4c substituents; Het.sup.B represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which Het.sup.B group is optionally substituted by one or more R.sup.4d substituents.

##STR00001##

According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A.sub.1-A.sub.2b or, particularly, the A.sub.2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy.sup.1 or Het.sup.A; Cy.sup.1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy.sup.1 group is optionally substituted by one or more R.sup.4a substituents; Het.sup.A represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more hetermatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy.sup.2 or Het.sup.B; Cy.sup.2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy.sup.2 group is optionally substituted by one or more R.sup.4c substituents; Het.sup.B represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which Het.sup.B group is optionally substituted by one or more R.sup.4d substituents.

##STR00001##

Provided herein are methods of treating a subject who has a viral respiratory infection, comprising administering to the subject a therapeutically effective amount of a compound of formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof.

Provided herein are methods of treating a subject who has a viral respiratory infection, comprising administering to the subject a therapeutically effective amount of a compound of formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof.

Provided herein are methods of treating a subject who has a viral respiratory infection, comprising administering to the subject a therapeutically effective amount of a compound of formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof.

The present invention provides a compound that have excellent harmful arthropod controlling effects, the compounds being represented by formula (I) [wherein Q represents a group represented by formula Q1 or the like, Z represents an oxygen atom or a sulfur atom, A.sup.1 represents a nitrogen atom or CR.sup.6a, A.sup.2 represents a nitrogen atom or CR.sup.6b, A.sup.3 represents a nitrogen atom or CR.sup.6c, A.sup.4 represents CR.sup.1a or the like, A.sup.5 represents a nitrogen atom or CR.sup.6e or the like, A.sup.6 represents a nitrogen atom or CR.sup.6f, R.sup.6a represents a hydrogen atom or the like, R.sup.6b represents a C1-C6 chain hydrocarbon group or the like, R.sup.6c, R.sup.6e, R.sup.6f are identical to or different from each other, and each represents a C1-C6 chain hydrocarbon group or the like, R.sup.1a represents a C1-C6 chain hydrocarbon group or the like, R.sup.2 represents a C1-C6 chain hydrocarbon group or the like, R.sup.3 represents a C1-C6 chain hydrocarbon group or the like, and n is 0, 1 or 2] or its N oxide compound. ##STR00001##

Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds of Formula (I): ##STR00001##
pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The disclosure further relates to methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof.